{"id":"https://genegraph.clinicalgenome.org/r/74e05f4e-c4c2-4374-841f-67459cd12305v1.6","type":"EvidenceStrengthAssertion","dc:description":["*PLP1* has been reported in relation to both X-linked Pelizaeus-Merzbacher disease (PMD) and hereditary spastic paraplegia (SPG). Evidence suggests that these disorders are at different ends of the same clinical spectrum; the curation presented here is specifically for the more severe Pelizaeus-Merzbacher presentation. The *PLP1* gene encodes two major alternatively spliced transcripts: a full-length transcript that encodes PLP, and a transcript lacking the PLP specific domain in exon 3, known as DM20. Differing molecular mechanisms are known to cause these disorders, including overexpression of PLP/DM20 (commonly caused by large, multi-gene duplications including *PLP1* and resulting in \"classic\" PMD); missense variants resulting in misfolding of both PLP and DM20 (resulting in the more severe, \"connatal\" PMD); null variants (resulting in milder presentations of PMD or \"complicated\" SPG); and milder misfolding variants (often associated with the SPG phenotype). Note that though duplications are the most common mechanism of PMD, none are curated here, as most involve more genes than just *PLP1*. Though extensive functional evidence (including additional animal models) is available to support the link between *PLP1* and PMD, only a subset is presented here.\n\nIn summary, there is definitive evidence supporting the relationship between *PLP1* and X-linked Pelizaeus-Merzbacher disease. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on March 7, 2018 (SOP Version 5).","Variation in PLP1 has been associated with both Pelizaeus-Merzbacher disease (PMD) and hereditary spastic paraplegia (SPG).  Evidence suggests that these disorders are at different ends of the same clinical spectrum; the curation presented here is specifically for the more severe Pelizaeus Merzbacher presentation.  The PLP1 gene encodes for 2 major alternatively spliced transcripts: a full length transcript that encodes PLP, and a transcript lacking the PLP specific domain in exon 3, known as DM20. Differing molecular mechanisms are known to cause these disorders, including overexpression of PLP/DM20 (commonly caused by large, multi-gene duplications including PLP1 and resulting in \"classic\" PMD); missense variants resulting in misfolding of both PLP and DM20 (resulting in the more severe, \"connatal\" PMD); null variants (resulting in milder presentations of PMD or \"complicated\" SPG); and milder misfolding variants (often associated with the SPG phenotype).  Note that though duplications are the most common mechanism of PMD, none are curated here (as most involve more genes than just PLP1).  Though extensive functional evidence (including additional animal models) is available to support the link between PLP1 and PMD, only a subset is presented here."],"dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/74e05f4e-c4c2-4374-841f-67459cd12305","GCISnapshot":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21","calculatedEvidenceStrength":"Definitive","changes":{"id":"cg:summaryChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":"2025-09-08T10:58:20.653Z","role":"Publisher"},{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10006","date":["2018-03-07T17:00:00.000Z","2018-03-07T11:00:00.000Z"],"role":"Approver"}],"curationReasons":["ErrorClarification"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ac739ad6-d80b-4e6e-8e1b-c9524c7e0f4d_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","rdfs:label":"Lassuthova Family 2","family":{"id":"https://genegraph.clinicalgenome.org/r/ac739ad6-d80b-4e6e-8e1b-c9524c7e0f4d","type":"Family","rdfs:label":"Lassuthova Family 2","member":{"id":"https://genegraph.clinicalgenome.org/r/d736b9b7-ddb8-456e-90eb-912ba6916582","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","rdfs:label":"Lassuthova Family 2 Proband IV:1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Subclinical demyelinating polyneuropathy; cerebellar dysfunction with titubation and atactic\nmovements.","phenotypes":["obo:HP_0001347","obo:HP_0001252","obo:HP_0001263","obo:HP_0000639","obo:HP_0001583","obo:HP_0003487"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/add11c68-d059-4213-9a5a-65faae818f35_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","allele":{"id":"https://genegraph.clinicalgenome.org/r/59566c4c-cf68-4aae-9ef2-a9fce2f24bfa","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.191+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/265416"}}}}},"phenotypeFreeText":"Pelizaeus Merzbacher disease","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/d736b9b7-ddb8-456e-90eb-912ba6916582"}},{"id":"https://genegraph.clinicalgenome.org/r/17389b6c-b660-4d93-b487-cd946cd11c8b_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","rdfs:label":"Lassuthova Family 1","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/17389b6c-b660-4d93-b487-cd946cd11c8b","type":"Family","rdfs:label":"Lassuthova Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/1d4390f1-dd64-431c-9715-a7b61cd5a2c5","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","rdfs:label":"Lassuthova Family 1 Proband IV:1","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":4,"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Severe hypotonia noted in the neonatal period.  Nystagmus noted at 2 months of age.  History of increased tendon reflexes, bilateral Babinski sign, and spasticity.  Never able to sit independently, roll over, or speak.  Died at 4 years of age due to aspiration pneumonia.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7d1dd6cd-06e5-4e6e-ae6e-022a1f641d66_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","allele":{"id":"https://genegraph.clinicalgenome.org/r/8554ee93-c93b-40ce-b7f8-58e691ff2c89","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786726_103786732delinsA (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658683058"}}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Pelizaeus Merzbacher disease","phenotypePositiveAllelePositive":2,"proband":{"id":"https://genegraph.clinicalgenome.org/r/1d4390f1-dd64-431c-9715-a7b61cd5a2c5"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/efc332fa-3c39-4243-9d07-6da768c76155_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29486744","rdfs:label":"Lyahyai Family","estimatedLodScore":1.51,"family":{"id":"https://genegraph.clinicalgenome.org/r/efc332fa-3c39-4243-9d07-6da768c76155","type":"Family","rdfs:label":"Lyahyai Family","member":{"id":"https://genegraph.clinicalgenome.org/r/6337d8c7-6e34-46ec-acc6-4587687b0786","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29486744","rdfs:label":"Lyahyai Family Proband V-4","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"History of neonatal hypotonia and psychomotor delay.  Patient was unable to sit independently at 2 years of age.  Daily generalized seizures began at 8 months of age.  Upon examination at 5 years of age, patient exhibited failure to thrive (weight at less than 3rd percentile), microcephaly, and severe hypotonia.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/6043ce02-7ba5-4d6d-9773-fea25565c4fd_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29486744","allele":{"id":"https://genegraph.clinicalgenome.org/r/6f65ef46-acbd-432d-9de2-c7f893238e9e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786524C>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102528"}}}}},"meetsInclusionCriteria":true,"phenotypeFreeText":"Neonatal hypotonia, psychomotor delay, and epilepsy","phenotypePositiveAllelePositive":4,"proband":{"id":"https://genegraph.clinicalgenome.org/r/6337d8c7-6e34-46ec-acc6-4587687b0786"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}},{"id":"https://genegraph.clinicalgenome.org/r/51ea3230-9614-472f-af09-73936575d76c_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","rdfs:label":"Hoffman Zacharska Family F07","estimatedLodScore":1.2,"family":{"id":"https://genegraph.clinicalgenome.org/r/51ea3230-9614-472f-af09-73936575d76c","type":"Family","rdfs:label":"Hoffman Zacharska Family F07","member":{"id":"https://genegraph.clinicalgenome.org/r/6dd45e93-8b41-4cff-bcd7-62614fd3ad16","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","rdfs:label":"Hoffman Zacharska F07_IV-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":18,"detectionMethod":"The authors performed \"direct sequencing of all 7 exons and the promotoer region of the PLP1 gene.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Patient said to be affected with classical Pelizaeus-Merzbacher disease.","phenotypes":["obo:HP_0000646","obo:HP_0001285","obo:HP_0000648","obo:HP_0000639","obo:HP_0001290","obo:HP_0100660","obo:HP_0001263"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7d1658eb-d851-4bea-9d7c-4f20203da3f7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","allele":{"id":"https://genegraph.clinicalgenome.org/r/0c8e6bba-04b8-46b1-8c3e-49552ab7bedc","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.140T>C (p.Ile47Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/405941"}}}}},"meetsInclusionCriteria":true,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001285","obo:HP_0001263","obo:HP_0000646","obo:HP_0000639","obo:HP_0100660","obo:HP_0000648","obo:HP_0001290"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/6dd45e93-8b41-4cff-bcd7-62614fd3ad16"},"sequencingMethod":{"id":"cg:CandidateGeneSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_ad_other_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8353be11-17bb-4fb8-a593-12595f98cc0a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6a3445e4-0af7-4a49-8705-22fc3d6290ae","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-83","ageType":"AgeAtDeath","ageUnit":"Years","ageValue":12,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient is said to be affected with severe connatal Pelizaeus-Merzbacher disease.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/8353be11-17bb-4fb8-a593-12595f98cc0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/3bc04bea-3dba-4261-9168-b167f0965f6a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103790555A>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414104933"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/e9c504d6-ef69-4f9a-9d1f-461f1fc0686d_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/579b6d5e-c4b6-42a2-a6f8-b303d2e2aceb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28101371","rdfs:label":"Lu Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Per the authors: \"A 3-year-old boy was born at 38 weeks of gestation with a birth weight of 2774â€‰g. This boy is the only child of healthy and non-consanguineous parents. Family history is unremarkable. Soon after birth, automated auditory brainstem response hearing screening detected abnormalities with no detection of waves after the first wave. At that time, pendular nystagmus was also noted. Because he had feeding difficulties due to laryngeal wheezing, tube feeding was initiated. Brain magnetic resonance imaging at 6 months of age revealed a hypomyelination pattern (Figure 1). The patient exhibited severe developmental delay with no head control or meaningful language development. From these findings, connatal type PMD was suggested as a candidate diagnosis.\"","previousTesting":true,"previousTestingDescription":"Patient initially underwent chromosomal microarray testing; no PLP1 duplication was detected.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/e9c504d6-ef69-4f9a-9d1f-461f1fc0686d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28101371","allele":{"id":"https://genegraph.clinicalgenome.org/r/0e9d2716-a558-4d6a-957f-4e27d8d3c0e2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.718T>C (p.Phe240Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/198089"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/832d6e53-037f-4e99-a864-d7dfd8584acc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e9aae1fa-efdf-4ef7-8459-bb138ba23d21","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-71","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":4,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient said to be affected with classic Pelizaeus-Merzbacher disease.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/832d6e53-037f-4e99-a864-d7dfd8584acc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/9fe7ca5b-410a-483b-9c39-bbec9f3f54eb","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.98G>A (p.Cys33Tyr)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/420045"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/6043ce02-7ba5-4d6d-9773-fea25565c4fd_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6337d8c7-6e34-46ec-acc6-4587687b0786"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/7d1658eb-d851-4bea-9d7c-4f20203da3f7_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/6dd45e93-8b41-4cff-bcd7-62614fd3ad16"}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/63895672-fbca-4b40-b0f5-4f37988bb03c_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  In silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/24f2254c-2070-43fb-81a6-bd1322c4b5b9","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","rdfs:label":"Cailloux Proband 107","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"firstTestingMethod":"PCR","phenotypeFreeText":"All individuals \"presented with early impairment (before 3 months) of normal motor development associated with neurological signs...Early nystagmus was observed in [nearly] all patients...bobbing movements of the head and trunk, choreoathetotic movements of the lims, and cerebellar ataxia were observed between 6 and 18 months of age; progressive spastic paraplegia with pyramidal tract signs were clearly present after 2-4 years.\"","previousTesting":true,"previousTestingDescription":"Patients were selected for PLP analysis based on \"clinical, electrophysiological, and MRI criteria.\"  The 52 patients studied in this paper (42 with diagnosis of PMD, 10 with diagnosis of SPG) have been previously found not to have large PLP duplications or deletions.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/63895672-fbca-4b40-b0f5-4f37988bb03c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","allele":{"id":"https://genegraph.clinicalgenome.org/r/40cf8969-75d6-49a0-b178-effdbdf99503","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786655G>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102816"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/03016495-a52d-4c20-a967-aea72efd3bfe_proband_score_evidence_line","type":"EvidenceLine","dc:description":"This particular publication shows no evidence for gene impact, though in silico prediction tools predict a damaging effect, and the variant is not present in gnomAD.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffa2be2b-e29d-497c-b5ad-9f6eae65c202","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2773936","rdfs:label":"Gencic PM4 (GM9545)","ageType":"AgeAtDiagnosis","ageUnit":"Months","ageValue":3,"detectionMethod":"The authors \"constructed a series of primers (fig. 4) that...direct[ed] the synthesis of all seven exons from genomic DNA, via PCR amplification. Following amplification, the coding and untranslated regions of the PLP gene as well as the intron/exon junctions and 5'- and 3'-flanking regions[were] quickly sequenced by the standard dideoxy method.\"","firstTestingMethod":"PCR","phenotypes":["obo:HP_0000639","obo:HP_0001285","obo:HP_0000648","obo:HP_0001257","obo:HP_0001510","obo:HP_0002719","obo:HP_0002487","obo:HP_0001344","obo:HP_0001266","obo:HP_0000549","obo:HP_0001583","obo:HP_0010544","obo:HP_0002421"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/03016495-a52d-4c20-a967-aea72efd3bfe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/2773936","allele":{"id":"https://genegraph.clinicalgenome.org/r/16747ea1-c155-4f99-9f64-2edac26b09df","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.646C>T (p.Pro216Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11073"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/9b77cfbc-4010-4c9d-8b5b-3d410d22d439_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/57176bc8-b28b-47a4-b160-78f1ba6426d7","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-119","ageType":"AgeAtReport","ageUnit":"Years","ageValue":28,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient is said to be affected with classic PMD.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/9b77cfbc-4010-4c9d-8b5b-3d410d22d439_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/399a27ea-1f9b-4133-a6aa-8486b453a499","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103787963T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414104143"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/b1e138c1-adf0-45f3-bd00-b3a4d6b74acc_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c43cc888-434a-43de-859c-95d880285748","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-28","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient said to be affected with severe connatal Pelizaeus-Merzbacher disease.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b1e138c1-adf0-45f3-bd00-b3a4d6b74acc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/c451f8a9-8645-4482-a18b-ba562a0aaad6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103788484C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414104367"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/b66615aa-4e50-4763-b0ab-12aba5c798a8_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c84ce0c5-c651-4c2d-8cfd-bbd6263b9117","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-159","ageType":"AgeAtReport","ageUnit":"Months","ageValue":7,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient is said to be affected with severe connatal PMD.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/b66615aa-4e50-4763-b0ab-12aba5c798a8_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/33eddb5b-9a19-4d03-9349-0766d4b0159a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_000533.5(PLP1):c.128C>T (p.Thr43Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/11086"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/ad3c8e0b-a205-4acf-be5d-24db613e0bfe_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/7efffaac-e2bd-41e7-8407-53ec17e2466f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-106","ageType":"AgeAtReport","ageUnit":"Years","ageValue":4,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient said to be affected with severe connatal PMD.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ad3c8e0b-a205-4acf-be5d-24db613e0bfe_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/2b9d4b2e-143d-4b70-b52f-3552c922beb0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103785669T>G (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102030"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/14fceea7-3aff-4e72-8ffe-a85988bd6738_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No experimental data is provided to demonstrate gene impact.  In silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE data, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0048c5df-f1a7-414e-9769-72c30e5be80c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","rdfs:label":"Cailloux Proband 12","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"firstTestingMethod":"PCR","phenotypeFreeText":"All individuals \"presented with early impairment (before 3 months) of normal motor development associated with neurological signs...Early nystagmus was observed in [nearly] all patients...bobbing movements of the head and trunk, choreoathetotic movements of the lims, and cerebellar ataxia were observed between 6 and 18 months of age; progressive spastic paraplegia with pyramidal tract signs were clearly present after 2-4 years.\"","previousTesting":true,"previousTestingDescription":"Patients were selected for PLP analysis based on \"clinical, electrophysiological, and MRI criteria.\"  The 52 patients studied in this paper (42 with diagnosis of PMD, 10 with diagnosis of SPG) have been previously found not to have large PLP duplications or deletions.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/14fceea7-3aff-4e72-8ffe-a85988bd6738_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","allele":{"id":"https://genegraph.clinicalgenome.org/r/a0796716-0bd4-4193-b9bf-0664c566be90","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786527T>C (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102534"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/7a339535-a392-4def-898b-e964e21d8237_proband_score_evidence_line","type":"EvidenceLine","dc:description":"No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a0fbee71-2179-44ec-9fbf-017dd73f7f15","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","rdfs:label":"Hoffman Zacharska F32_IV-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"The authors performed \"direct sequencing of all 7 exons and the promotoer region of the PLP1 gene.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Individual is said to be affected with classical Pelizaeus-Merzbacher disease.","phenotypes":["obo:HP_0000648","obo:HP_0000639","obo:HP_0001263","obo:HP_0000646","obo:HP_0001285","obo:HP_0100660","obo:HP_0001290"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/7a339535-a392-4def-898b-e964e21d8237_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","allele":{"id":"https://genegraph.clinicalgenome.org/r/aef2f275-fc3b-4902-a526-e5c29d7a24f9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103788440T>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414104210"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/c2cb53e9-0c5e-49cd-94ae-1ae673754d6a_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Opting not to award this case any points.  Though the variant is absent from the gnomAD, PAGE, 1000 Genomes, and ESP datasets, there is no functional evidence provided to demonstrate the variant's gene impact, and in silico predictors do not predict a damaging effect.","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/12e8f4ec-8864-4976-945a-6a6e596f5215","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","rdfs:label":"Cailloux Proband 41","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"firstTestingMethod":"PCR","phenotypeFreeText":"All individuals \"presented with early impairment (before 3 months) of normal motor development associated with neurological signs...Early nystagmus was observed in [nearly] all patients...bobbing movements of the head and trunk, choreoathetotic movements of the lims, and cerebellar ataxia were observed between 6 and 18 months of age; progressive spastic paraplegia with pyramidal tract signs were clearly present after 2-4 years.\"","previousTesting":true,"previousTestingDescription":"Patients were selected for PLP analysis based on \"clinical, electrophysiological, and MRI criteria.\"  The 52 patients studied in this paper (42 with diagnosis of PMD, 10 with diagnosis of SPG) have been previously found not to have large PLP duplications or deletions.","secondTestingMethod":"Sanger sequencing","sex":"UnknownEthnicity","variant":{"id":"https://genegraph.clinicalgenome.org/r/c2cb53e9-0c5e-49cd-94ae-1ae673754d6a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/11093273","allele":{"id":"https://genegraph.clinicalgenome.org/r/20c18c34-e748-4415-a5a2-1ec49e5fee8e","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103787889C>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414103868"}}}}],"specifiedBy":"GeneValidityProbandADNonNullCriteria","strengthScore":0}],"specifiedBy":"GeneValidityOverallAutosomalDominantOtherVariantEvidenceCriteria","strengthScore":3.25},{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_ad_null_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f7d491c7-7e19-4450-91a5-ab1efa92eee5_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Per the authors: \"Transcript analysis in our male patient, however, showed that only part of exon 5 is skipped due to the usage of a cryptic intraexonic splice site, which results in an in-frame deletion of 14 codons...We did not detect any normal transcript in our patient fibroblasts [only aberrant transcripts were detected],which is in agreementwith predicted site inactivation. It remains uncertain whether an aberrant PLP1/DM20 protein still retains some physiological function.\"","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d58d21da-6fd0-4900-a0f7-25251ec9e7cb","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","rdfs:label":"Lassuthova Proband 3","ageType":"AgeAtReport","ageUnit":"Years","ageValue":9,"firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Classic Pelizaeus Merzbacher phenotype; early-onset, subclinical demyelinating neuropathy; diffuse white matter hyperintensity; developmental delay; severe spastic quadriparesis","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/f7d491c7-7e19-4450-91a5-ab1efa92eee5_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23771846","allele":{"id":"https://genegraph.clinicalgenome.org/r/654a885f-a2cd-407e-b8c9-87dd519f1d6a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103788511G>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414104455"}}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/7d1dd6cd-06e5-4e6e-ae6e-022a1f641d66_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1d4390f1-dd64-431c-9715-a7b61cd5a2c5"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/43488bd2-2288-41c3-a493-6886360f959e_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e115800-4d05-4bcc-be66-019237044149","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","rdfs:label":"Martinez Montero PM-121","ageType":"AgeAtReport","ageUnit":"Years","ageValue":8,"detectionMethod":"All individuals were tested via PLP1 custom oligonucleotide array-CGH (includes the PLP1 gene and neighboring genes within 10Mb; average resolution is around 600 bp).  Those that were negative for large genomic duplications including PLP1 underwent sequencing.","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Congenital hypomyelination and clinical diagnosis of leukodystrophy based on MRI.  Patient is said to be affected with PLP null syndrome.","previousTesting":true,"previousTestingDescription":"Per the authors: \"In the majority of patients, other causes of leukodystrophy had been ruled out.\"  No further details are provided.","sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/43488bd2-2288-41c3-a493-6886360f959e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/23347225","allele":{"id":"https://genegraph.clinicalgenome.org/r/8d4a50ed-67d6-4f31-b263-839d4aa352a7","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786636_103786640del (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA658683056"}}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/12f8086e-1c25-4499-9be8-9fa110e664ba_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0aa2906b-28e3-445d-8cdd-4543aa55fb2b","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","rdfs:label":"Hoffman Zacharska F01_II-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":15,"detectionMethod":"The authors performed \"direct sequencing of all 7 exons and the promotoer region of the PLP1 gene.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"This individual is said to be affected with classic PMD.","phenotypes":["obo:HP_0000639","obo:HP_0000648","obo:HP_0000646","obo:HP_0100660","obo:HP_0001285","obo:HP_0001263","obo:HP_0001290"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/12f8086e-1c25-4499-9be8-9fa110e664ba_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","allele":{"id":"https://genegraph.clinicalgenome.org/r/b2abc282-2280-4c06-91d3-4c2160cb1e68","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786658C>T (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102823"}}}}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/add11c68-d059-4213-9a5a-65faae818f35_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d736b9b7-ddb8-456e-90eb-912ba6916582"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":7},{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3d27ee6f-b1c9-4e21-bf6a-4d5ca288f5c3_proband_score_evidence_line","type":"EvidenceLine","dc:description":"Downgrading because the variant is missense.  No functional evidence is provided to demonstrate this variant's gene impact.  However, in silico predictors predict a damaging effect, and the variant is absent from gnomAD, PAGE, 1000 Genomes, and ESP.","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2ea18c5c-4b9e-4b47-9b7f-08173ac3e32e","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","rdfs:label":"Hoffman Zacharska F28_II-1","ageType":"AgeAtReport","ageUnit":"Years","ageValue":12,"detectionMethod":"The authors performed \"direct sequencing of all 7 exons and the promotoer region of the PLP1 gene.\"","firstTestingMethod":"Sanger sequencing","phenotypeFreeText":"Patient is described as having classical Pelizaeus-Merzbacher disease.","phenotypes":["obo:HP_0001285","obo:HP_0001263","obo:HP_0100660","obo:HP_0000639","obo:HP_0000646","obo:HP_0001290","obo:HP_0000648"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/3d27ee6f-b1c9-4e21-bf6a-4d5ca288f5c3_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/24519770","allele":{"id":"https://genegraph.clinicalgenome.org/r/534bdaa4-be2d-4e99-9cbb-84f29bc3e2c8","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000023.11:g.103786536C>A (GRCh38)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA414102550"}},"alleleOrigin":{"id":"cg:DeNovoAlleleOrigin"},"paternityMaternityConfirmed":"No"}}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c1a44c5f-744e-4d02-a08f-e7c687531b21_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/f1e414d4-cca2-45f0-b0cf-3f340da151e1","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8a4ab663-8b08-4318-bdcd-aa43bd44c4d3","type":"Finding","dc:description":"Per the authors, jimpy mice are characterized by a \"characteristic body tremor preceding locomotor activity [beginning around] postnatal day 11...later, convulsions develop and death occurs in the 5th week...Histological studies of jimpy mice reveal an almost complete absence of white matter in the central nervous system.\"  The mice are also said to have \"a drastic decrease of structural myelin proteins...\"  This is similar to the dysmyelination observed in humans.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/3466187","rdfs:label":"Nave Jimpy Mouse","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/3bf77a7a-b912-4afd-b83a-89cffaf5440d","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d4482b83-c915-4350-ae4f-12d0b1269e2a","type":"Finding","dc:description":"Per the authors: \"The shaking pup arose spontaneously in a line of springer spaniels and is characterized by a severe termor beginning at about 12 days of age followed by late onset convulsions, and, under natural conditions, an early death by about 3-4 months of age...the CNS exhibits severe hypomyelination and a reduction in the number of mature oligodendrocytes.\"  This is similar to the hypomyelination observed in humans.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/1723945","rdfs:label":"Nadon Shaking Pup","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":4}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":11579,"specifiedBy":"GeneValidityCriteria5","strengthScore":16,"subject":{"id":"https://genegraph.clinicalgenome.org/r/CLmUm5E5Bgw","type":"GeneValidityProposition","disease":"obo:MONDO_0010714","gene":"hgnc:9086","modeOfInheritance":"obo:HP_0001417"},"version":"1.6","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_c1a44c5f-744e-4d02-a08f-e7c687531b21-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}